30 closest matches · ranked by relevance
MDR-TB
Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants
Tuberculosis
Primary: TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3…
Recurrent Tuberculosis
Primary: Sputum Culture Conversion Rates at Week 8 and Month 6 Post Tuberculosis Treatment Initiation — 78; 73; 84; 92 Participants — p=0.46
Tuberculosis
Primary: Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18…
Tuberculosis
Primary: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat — 13; 3 Participants
Tuberculosis, Pulmonary
Primary: Rate of TB Disease Recurrence (Relapse or Reinfection), Defined as TB Diagnosed by Confirmation of Mtb by Culture of Sputum. — 23; 14; 377; 392 Participants — p=0.9558
Tuberculosis · HIV Infections
Primary: Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause — 0.6506; 0.6736 Events per 100 person-years
Pulmonary Tuberculosis
Primary: Number of Adverse Events — 5; 4; 10; 8 participants
Tuberculosis
Primary: Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication — 6; 3 participants — p=>.05
Pulmonary Tuberculosis
Primary: Number of Participants Suffering From Treatment Failure/ Relapse (Unfavourable Outcome) Among Rifampicin Resistant Group. — 12; 8; 67; 73 participants
Tuberculosis · Multi-Drug Resistant Tuberculosis
Primary: Changes in TB Lesion Sizes Using High Resolution Computed Tomography (HRCT). — 8.11; 10.08; 6.64; 7.24 reader score
Lung Tuberculosis · MDR TB
Primary: Number of MDR TB Cases Amongst New TB Cases and Previously Treated TB Cases — 23; 64 Participants
Pulmonary Tuberculosis
Primary: Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C — 217; 121; 117; 5 Participants
Tuberculosis · AIDS-related Complex
Primary: Sputum Conversion — 36; 60; 36 percentage of participants
Latent Tuberculosis Infection
Primary: TST Induration Will be Interpreted Relative to Risk, in Accordance With Published CDC Guidelines. — 2; 37; 20 participants
Tuberculosis
Primary: Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14 — -0.199; -0.017; -0.092; -0.092…
Tuberculosis
Primary: Percentage of Participants With Negative Lowenstein Jensen Cultures at Week 8 — 85; 94; 96 percentage of participants w/LJ cx con
Tuberculosis
Primary: Steady State Pharmacokinetic Exposure of RIF — 115.6988; 201.9725; 284.4278 Ratio
Tuberculosis
Primary: Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14 — 0.134; 0.096; 0.136; 0.119…
Tuberculosis
Primary: Number of Healthy Participants Negative for Reaction at 24 Hours After Intradermal Injection With ESAT6-CFP10 — 13; 13; 14; 13 participants
Tuberculosis · HIV Infections
Primary: Number of Participants With Incident Tuberculosis — 20; 34 Participants
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Tuberculosis · Alcohol Consumption · Treatment Adverse Effect
Primary: Time to Culture Conversion — 5.6; 5.4; 5.5 weeks
Tuberculosis
Primary: Clearance Relative to Bioavailability (CL/F) for Rifapentine (RPT) for Intensive and Sparse PK — 1.4; 1.50 L/hr
Tuberculosis
Primary: Daily Change in log10 Colony-forming Unit (CFU) — -0.06; -0.18; -0.21; -0.15 log10 CFU per mL sputum per day
HIV Infection
Primary: Cumulative Probability of Death or Unknown Vital Status by Week 24 — 5.2; 5.2 Cumulative probability per 100 persons — p=0.97
Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, MDR
Primary: Incidence of Bacteriologic Failure or Relapse or Clinical Failure (Unfavorables) Through Follow up Until 26 Weeks After the End of Treatment — 41; 40; 41; 37 Participants
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14)…
Latent Tuberculosis
Primary: Feasibility: Participant Attendance — 10; 9; 7; 8 participants
Tuberculosis
Primary: Sputum Bacillary Loads: Adjusted Area Under the Curve (aAUC) — 0.98; 0.98; 0.96; 0.95 Percentage — p=<0.001